Flagship VentureLabs and Children’s Hospital Boston spin out ModeRNA Therapeutics to commercialize researchers’ discovery of a way to reprogram human skin cells so that they become stem cells, bypassing the creation of stem cell lines from human embryos.
Hot on the heels of the announcement of a revolutionary method of creating stem cells without destroying human embryos, the Harvard researchers who discovered the technique are spinning out a company to commercialize it.
Researchers at Boston’s Harvard Stem Cell Institute discovered a way to reprogram human skin cells so that they become stem cells, bypassing the creation of stem cell lines from human embryos.
With the Rise of AI, What IP Disputes in Healthcare Are Likely to Emerge?
Munck Wilson Mandala Partner Greg Howison shared his perspective on some of the legal ramifications around AI, IP, connected devices and the data they generate, in response to emailed questions.
Research published in the journal Cell Stem Cell details how the team, led by Derrick Rossi, used RNA from stem cells to transform ordinary skin cells into induced pluripotent stem cells. The technique avoids using a virus to carry new genes into the cells — and the controversial destruction of human embryos to derive stem cells.
That technique is at the heart of high-profile legal wrangling between the U.S. government and two researchers who sued to stop federal funding of research using stem cells from embryos. Judge Royce Lamberth of the U.S. District Court for the District of Columbia ruled late in the summer that federal funds could not be used for the the research, derailing scores of projects looking into the causes of diseases like Parkinson’s, Alzheimer’s and cystic fibrosis. President Barack Obama had sought to restore stem cell research funding from constraints imposed under the Bush administration, but Lamberth ruled that the policy violated the Dickey-Wicker Amendment, aimed at stopping the destruction of human embryos. This week a three-judge panel on a federal appeals lifted Lamberth’s injunction barring the funding.
Now Rossi’s team’s discovery may make the case a moot point. At any rate, Rossi will lead the new company, ModeRNA Therapeutics, with backing from Flagship VentureLabs, according to a press release.
Here’s a video explaining the new technique:
A Personalized Approach to Medication Nonadherence
At the Abarca Forward conference earlier this year, George Van Antwerp, managing director at Deloitte, discussed how social determinants of health and a personalized member experience can improve medication adherence and health outcomes.
The Massachusetts Medical Devices Journal is the online journal of the medical devices industry in the Commonwealth and New England, providing day-to-day coverage of the devices that save lives, the people behind them, and the burgeoning trends and developments within the industry.
